Toleranzia (TOL) Q4 2024 earnings summary

Executive summary

• Achieved key regulatory milestones for TOL2, including successful GLP toxicology and clinical trial application approval in Sweden and Germany for myasthenia gravis therapy.

• Secured approximately SEK 37 million through TO4 warrant exercise, reflecting strong investor confidence.

• Focused on finalizing GMP drug product formulation and clinical trial logistics for TOL2 Phase I/IIa trial.

Financial highlights

• Operating loss for Q4 was KSEK -4,206 (vs. -2,122 YoY); full year operating loss was KSEK -10,248 (vs. -7,891 YoY).

• Cash flow from operating activities for Q4 was KSEK -8,513 (vs. -2,895 YoY); full year was KSEK -10,281 (vs. -6,323 YoY).

• Investments in intangible assets for the year totaled KSEK 30,026 (vs. 50,778 YoY).

• Cash and bank balances at year-end were KSEK 13,777 (vs. 18,304 YoY).

• Earnings per average share for the year were SEK -0.04 (vs. -0.06 YoY).

Outlook and guidance

• Additional capital will be required to fully fund the Phase I/IIa trial; Board is evaluating financing options.

• No dividend proposed for AGM 2025.

• Focus remains on initiating TOL2 clinical trial and advancing drug development pipeline.